Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH2853 vs investigator's choice standard therapy in first-line advanced epithelioid sarcoma
CTR20255213Phase 3Active
- Sponsor
- Haihe
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HH2853 in epithelioid sarcoma (ES), sponsored by Haihe. Started Feb 2026; status: active.
02
Drugs
HH2853
03
Conditions
epithelioid sarcoma (ES)
Beyond the preview
Go deeper on CTR20255213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255213.